Epcoritamab plus chemo for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of aggressive B-cell lymphoma (like diffuse large B-cell lymphoma or high-grade B-cell lymphoma with certain genetic features) that hasn't been treated with chemo before (one cycle is allowed).
- You are 18 or older and willing to give written consent.
- You have at least one tumor that can be measured on a scan (1.5 cm in a lymph node or 1 cm elsewhere).
- You are generally active (can take care of yourself, up to needing some help).
- Your heart, kidneys, liver, and blood counts meet specific safety levels (tested by your doctor).
- You agree to use effective birth control during the study and for a period after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.